Adalimumab-Adaz Coupons & Prices

Looking for an adalimumab-adaz coupon? Adalimumab-adaz is the nonproprietary name for Hyrimoz, an FDA-approved biosimilar to Humira, and pricing for it can differ a lot from one pharmacy to the next. Rx.com compares 60,000+ pharmacies so you can see where a given fill costs less before you head to the counter; enter your ZIP above to see today's price near you.

What Is Adalimumab-adaz (Hyrimoz)?

Adalimumab-adaz, sold under the brand name Hyrimoz (including a high-concentration, citrate-free version), is a TNF-alpha inhibitor, a biosimilar version of the biologic drug Humira. It's FDA-approved for a number of inflammatory conditions, including moderately to severely active rheumatoid arthritis in adults, juvenile idiopathic arthritis in patients 2 and older, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe Crohn's disease and ulcerative colitis, moderate-to-severe chronic plaque psoriasis, hidradenitis suppurativa in patients 12 and older, and certain forms of uveitis. It's given by subcutaneous (under-the-skin) injection, typically self-administered every other week, though some people use it weekly depending on the condition being treated and other medications they're on.

Adalimumab-adaz Cost Without Insurance

There is no generic version of adalimumab-adaz itself. It's a biosimilar biologic, not a small-molecule generic drug, so it's dispensed as the brand-name product Hyrimoz. Pricing for biologic injectables like this can vary significantly by pharmacy and by which Hyrimoz formulation (standard or high-concentration, citrate-free) is dispensed, which is why it's worth comparing before you fill. Enter your ZIP code above to see today's price at pharmacies near you.

The manufacturer also offers a savings and support program for eligible patients through the official Hyrimoz website. Terms, eligibility, and insurance requirements vary, so check directly with the manufacturer for current details.

Hyrimoz vs. Humira and Other Adalimumab Biosimilars

Hyrimoz is one of several FDA-approved biosimilars to Humira (adalimumab). A biosimilar is highly similar to its reference biologic, with no clinically meaningful differences in safety or effectiveness, but it isn't an identical copy the way a traditional generic tablet is, since biologics are manufactured from living cells and exact duplication isn't possible. Other adalimumab biosimilars on the market include adalimumab-adbm, adalimumab-atto, and adalimumab-fkjp. Depending on the condition being treated, your provider may also discuss other biologic options such as etanercept or infliximab, or a conventional disease-modifying drug like methotrexate. Switching between Humira and Hyrimoz, or between different adalimumab biosimilars, should only be done with your prescriber's guidance.

Safety Information and Side Effects

Hyrimoz carries boxed warnings, the FDA's most serious type, for an increased risk of serious infections that can lead to hospitalization or death, including tuberculosis, bacterial sepsis, invasive fungal infections such as histoplasmosis, and other opportunistic infections; patients are screened for latent TB before starting and monitored throughout treatment. It also carries a boxed warning for an increased risk of lymphoma and other cancers, some fatal, in children and adolescents treated with TNF blockers, including a rare, aggressive, often-fatal hepatosplenic T-cell lymphoma reported mainly in young males with inflammatory bowel disease who were also taking azathioprine or 6-mercaptopurine. Common, less serious side effects include injection-site reactions, upper respiratory infections, headache, and rash. This isn't a complete list, talk with your prescriber about your full medical history and any symptoms before and during treatment.